Please login to the form below
Jounce
This page shows the latest Jounce news and features for those working in and with pharma, biotech and healthcare.
Celgene cuts back Jounce alliance ahead of BMS merger
Despite the thinning down of the alliance, the news was greeted enthusiastically by Jounce investors, with its shares rising more than 30% on Wednesday. ... Jounce must now deliver positive results from its phase 2 EMERGE clinical trial of vopratelimab
Latest news
-
Bluebird and Celgene BCMA CAR-T kicks off ASCO
That includes data on Jounce Therapeutics’ ICOS-targeting antibody JTX-2011 which disappointed investors when the ASCO abstract was made public earlier this month, as well as Celldex’ anti-CD27 agonist
-
Immuno-oncology at ASCO: survival data, combinations and new indications
Standout examples of that this year include Jounce Therapeutics - which fell dramatically after data from a phase I trial of its ICOS agonist antibody JTX-2011 alongside Bristol-Myers Squibb’s
-
Celgene pays $300m upfront for immunology start-up Delinia
$43.5m and a $2.5bn licensing deal with Jounce for five immuno-oncology candidates.
-
Jounce bags $225m upfront in Celgene immuno-oncology deal
Celgene has bolstered its immuno-oncology pipeline in an agreement with US biotech Jounce Therapeutics that gives it options on five experimental cancer therapies. ... According to Jounce Celgene was one of several companies trying to close a licensing
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch July 2016
Licensee. Licensor. Headline. Upfront. Equity. Near-term R&D funding. Celgene. Jounce. $2, 561m. ... Jounce Therapeutics/ Celgene. Portfolio and platform of biomarker driven immuno-oncology therapeutics and CDx.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Hugh Cole joins Jounce Therapeutics as chief business officer
US clinical-stage pharmaceutical company Jounce Therapeutics has appointed Hugh Cole as its new chief business officer and head of corporate development. ... We are thrilled to welcome him to Jounce at a critical point in our drug development process.”.
-
Constellation Pharmaceuticals appoints Jigar Raythatha as CEO
Raythatha re-joins the firm from Jounce Therapeutics where he was chief business officer, leading its business strategy and development since December 2012.
-
Merck’s Richard Murray joins Jounce as CEO
pembrolizumab. This experience will benefit Jounce, a Cambridge, Massachusetts-based company that specialises in cancer immunotherapies. ... The new CEO sees potential in Jounce, however, with the prospect of cancer immunotherapies an appetising one for
More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Director, Healthcare Communications
-
Salary TBC
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
